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Abstract
Background: Despite the established evidence and theoretical advances explaining human judgments under
uncertainty, developments of mobile health (mHealth) Clinical Decision Support Systems (CDSS) have not explicitly
applied the psychology of decision making to the study of user needs. We report on a user needs approach to
develop a prototype of a mHealth CDSS for Parkinson’s disease (PD), which is theoretically grounded in the
psychological literature about expert decision making and judgement under uncertainty.
Methods: A suite of user needs studies was conducted in 4 European countries (Greece, Italy, Slovenia, the UK)
prior to the development of PD_Manager, a mHealth-based CDSS designed for Parkinson’s disease, using wireless
technology. Study 1 undertook Hierarchical Task Analysis (HTA) including elicitation of user needs, cognitive
demands and perceived risks/benefits (ethical considerations) associated with the proposed CDSS, through
structured interviews of prescribing clinicians (N = 47). Study 2 carried out computational modelling of prescribing
clinicians’ (N = 12) decision strategies based on social judgment theory. Study 3 was a vignette study of prescribing
clinicians’ (N = 18) willingness to change treatment based on either self-reported symptoms data, devices-generated
symptoms data or combinations of both.
Results: Study 1 indicated that system development should move away from the traditional silos of ‘motor’ and
‘non-motor’ symptom evaluations and suggest that presenting data on symptoms according to goal-based
domains would be the most beneficial approach, the most important being patients’ overall Quality of Life (QoL).
The computational modelling in Study 2 extrapolated different factor combinations when making judgements
about different questions. Study 3 indicated that the clinicians were equally likely to change the care plan based on
information about the change in the patient’s condition from the patient’s self-report and the wearable devices.
Conclusions: Based on our approach, we could formulate the following principles of mHealth design: 1) enabling
shared decision making between the clinician, patient and the carer; 2) flexibility that accounts for diagnostic and
treatment variation among clinicians; 3) monitoring of information integration from multiple sources. Our approach
highlighted the central importance of the patient-clinician relationship in clinical decision making and the relevance
of theoretical as opposed to algorithm (technology)-based modelling of human judgment.
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Summary points
 There has been limited evidence of the widespread
implementation and acceptance of mHealth based
Clinical Decision Support Systems (CDSS).
 The needs of the users of mHealth CDSS (i.e.
clinicians) in terms of the cognitive demands of
clinical decision making under uncertainty are not
explicitly explored in the of design mHealth-based
CDSS.
 Our research on clinicians’ user needs for the
development of Parkinson’s mHealth-based CDSS is
theoretically grounded in the psychological literature
about expert decision making and judgement under
uncertainty.
 It highlighted the central importance of the patient-
clinician relationship in clinical decision-making and
the relevance of theoretical as opposed to algorithm
(technology)-based modelling of human judgment.
Background
We are currently witnessing a paradigm shift in the global
provision of healthcare, as new technologies are emerging
to address growing challenges of cost, quality and continu-
ity of healthcare provision. Rapid technological develop-
ments such as mobile health technologies (mHealth) and
data analytics, offer solutions to the current unsustainable
healthcare systems. “Mobile health” (mHealth), is defined
as “medical and public health practice supported by mo-
bile devices, such as mobile phones, patient monitoring
devices, personal digital assistants and other wireless de-
vices” [1]. mHealth is incorporated within the broader
health informatics framework, though has emerged as a
distinctive system in terms of context of use and accept-
ance. The pervasiveness, portability, convenience, immedi-
acy and ubiquity of mobile devises enables not only
continuous monitoring and communication required for
the management of chronic conditions by healthcare pro-
viders at lower costs, but also patient empowerment to
self-manage chronic conditions. Furthermore, the unique
feature of mHealth is its ability to collect and connect
medical, health-related and non-medical (e.g., behavioural)
information that can feed into the existing health inform-
atics systems such as electronic medical records and hos-
pital information systems. This potentially innovative
aspect of mHealth solutions, however, is currently largely
confined to the non-healthcare context (e.g. lifestyle and
public health applications) and lacking in acceptable
frameworks for its wider adoption into the healthcare sys-
tems [2, 3] . Diffusion of new technologies necessitates
clarifying the actual purpose of the innovations both from
the point of view of healthcare system and the immediate
needs of the users of the system, including patients and
clinicians.
The need for mHealth-based clinical decision-support
system
For a health informatics system to be useful it needs
to address all the complex cognitive needs of a clini-
cian’s task. Medical decision making, especially con-
cerning chronic conditions, is characterised by
considerable complexity as it is often based on uncer-
tain and incomplete information and therefore relies
on the clinician’s expertise. The diversity of patient
presentation and complexity of symptoms, time con-
straints, characteristics of patient–clinician encounter,
and limitations of diagnostic tests all increase uncer-
tainty in medical decision making, resulting in poor
patient outcomes and increased costs [4–11]. Diag-
nostic uncertainty is ostensibly a subjective
phenomenon based on the perceived lack of reliable
information for treatment decisions [5].
The advances in mHealth such as data analytics and al-
gorithm development based on continuous capture of a
wide range of structured and unstructured patient-related
data, can be harnessed to address such uncertainties
through a Clinical Decision-Support System (CDSS) [12,
13], a software that can aid clinical decision making
through careful matching of the patient individual factors
(e.g., age, sex, ethnicity, computer literacy), their behaviour
(in-situ and self-reported behaviour) and their current
health status, with a computerised clinical knowledge base
in order to provide patient-specific assessment and recom-
mendations about clinical diagnosis/management [14]. A
mHealth-based CDSS offers the potential to reduce med-
ical errors [15] and improve the quality and efficiency of
healthcare [16]. Nevertheless, actual application of such
systems to date has been limited [17]. Several systematic
reviews have examined the ability of mobile technology-
based interventions designed to improve healthcare service
delivery [18, 19]. Free et al. [18] identified a small improve-
ment in outcomes relevant to clinical diagnosis, though the
potential errors in reports and time taken to process data
do caution against a wholesale and uncritical adoption of
mHealth solutions. Bright et al. [20] similarly suggested
that the evidence of their impact on clinical and economic
effectiveness, user satisfaction and usefulness is ambiguous,
with a range of studies variously demonstrating high, low
and no difference in satisfaction and usefulness after intro-
ducing such CDSS’s in clinical decision making. The au-
thors conclude that understanding the ways in which
CDSS can meaningfully enhance specific clinical roles is a
necessary next step towards the successful implementation
of mHealth-based CDSS. In developing a mHealth CDSS,
therefore, user-centred design is essential.
In software engineering, user-centred design comprises
several key aspects: a) analysis of users’ characteristics
and work environments; b) top level functional analysis
of users’ goals, the domain structures needed for
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successful goal completion, and information flows within
a system; c) tasks analysis; and d) representational ana-
lysis of user interface [21]. These software engineering-
driven analytical strategies are mostly performed
through ‘use cases’ - the industry standard for establish-
ing system requirements. Whilst a use case approach fa-
cilitates requirement- gathering and subsequent
description of the functional requirements of a system
from a goal-based user perspective [22], it centres on the
system architecture and system/service quality rather
than the system user, is iterative and incremental, and
mainly driven by the already established system proto-
type. By contrast, a fully user-centred approach precedes
the development of the prototype and provides a nu-
anced understanding of intended users’ needs before the
process of software development even commences.
In this paper, we report on research of user needs to
inform and provide first principles for the development
of the prototype of a mHealth CDSS [23] for a complex
neurodegenerative condition – Parkinson’s disease (PD).
Focusing on this particular chronic condition, our aim is
to present a novel approach to establishing user needs,
utilising a suite of methodologies that can be applied to
a range of disorders. These methodologies are theoretic-
ally grounded in the psychological literature about ex-
pert decision making and judgement under uncertainty.
Thus, they address the gap in the currently reported user
studies for the development of CDSS which often lack a
theoretical basis for their study design [24]. The unique
characteristics of PD provide a fertile ground for the im-
plementation of a CDSS based on mHealth, but due to
its complexity, also present many challenges.
Parkinson’s was chosen because of its high prevalence in
older adults and its complex and ever fluctuating symp-
tom range. PD is the second most common neurodegen-
erative disorder in Europe with more than 1 million
people living with the disease in Europe today and this
number is forecast to double by 2030 [25]. The economic
impact of the disease is substantial – the annual European
cost is estimated at €13.9 billion [26]. Parkinson’s is a
complicated disorder that most patients live with for many
years and decades, becoming increasingly reliant on others
to care for them in all aspects of life. The highly idiosyn-
cratic presentation of the disease, its unpredictable pro-
gression, the plethora of possible symptoms both motor
(tremor, bradykinesia, rigidity as well as gait/postural bal-
ance, speech disorders, swallowing disorders) and non-
motor (cognitive disorders/dementia, depression and anx-
iety, Impulse Control Disorders, sleep disorders), as well
as their daily and hourly fluctuation (e.g. motor on-off
fluctuations, including freezing and dyskinesia’s, and non-
motor fluctuations) render the disease particularly difficult
to manage. The treatment is typically pharmacological,
supplemented by occasional rehabilitative therapies, and
in some cases, surgery. Clinical decisions are usually based
on routine patient-clinician meetings (every 3–6months).
In that context, clinician reliance on patient and carers’
self-reports may be problematic. The presenting state of
the patient may not indicate the extent and nature of
functional impairments that are experienced at other
points in time meaning that the clinician cannot gain a full
and accurate picture of the patient’s status and the disease
fluctuations that are crucial for appropriate titration of
pharmacological treatment. Thus, a CDSS delivering a
continuous stream of information via a mHealth solution
has many obvious attractions, due to its pervasiveness,
portability, context-sensitivity, immediacy and conveni-
ence [27].
User-centred development of CDSS based on mHealth
A mHealth-based CDSS promises to deliver objective data
about the patient’s healthcare status to the clinician in a
timely manner [1] but, at the same time, risks increasing
“technical uncertainty” [4], that is, the uncertainty due to
the increased amount of available information, but not ne-
cessarily its utility, in making medical decisions. In addition,
it has been shown that human beings tend to rely more on
human judgement rather than on evidence-based algo-
rithms, despite the latter being better predictors in many
contexts (a phenomenon called “algorithm aversion” [28]).
An effective CDSS must be able to collect and link
numerous types of patient-related data, be they physio-
logical, pharmacological, behavioural and/or psychological
measures. When developing the CDSS, a decision must be
made about what types of data will be collected, con-
nected and ultimately delivered to the clinician to opti-
mise their judgment. Optimizing medication is the key for
the management of PD and to support such functionality,
the CDSS must employ algorithms that transform the
stream of patient data into recognised symptoms (in order
to recognise a patient’s state), and then to proposed deci-
sions about the treatment plan. To develop accurate deci-
sion support systems, merely providing patient data is not
enough; it needs to identify underlying expert models of
decision making and compare the data against these ex-
pert models and clinical guidelines [29].
This includes an understanding of how clinicians in-
terpret and respond to uncertain evidence. The latter is
particularly relevant to PD given its multifaceted, com-
plex and fluctuating nature [30–33]. It is important to
understand whether and to what extent clinicians per-
ceive a certain piece of evidence as informative and
whether it is coming from a subjective information
source (e.g., patient self-reports, diaries, questionnaires)
or from an objective source e.g., wearable digital health
technology, neuropsychological assessments, medical as-
sessment techniques (such as Magnetic Resonance Im-
aging (MRI), blood samples) [34–36].
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Early user (clinician) engagement with the design
process and well-structured studies of user needs and
their cognitive demands are therefore a necessary compo-
nent of mHealth-based CDSS design and essential to in-
creasing the usefulness, efficacy and acceptability of
mHealth technologies. However, user engagement in the
development of the CDSS is poorly reported and often
given only a cursory role in the design. There is limited
evidence of extensive exploration of clinicians’ decision-
making processes, and how interventions will fit into rou-
tine clinical workflow. Previous design projects on CDSS
for Parkinson’s, PERFORM [37], REMPARK [38] and
SENSE-PARK [39], surveyed the factors influencing clini-
cians’ pharmacological decision-making – for instance,
Serrano et al. [24] report on the participatory design
process to achieve a consensus among patients, clinicians
and technologists over the selection of a set of symptom
domains to be continuously assessed. The reviewed pro-
jects, however, mainly focused on information needs and
none examined in-depth the clinicians’ expert judgement
models that are active in situ – the contexts characterised
by the specific presentation of symptoms. Importantly,
none of these approaches were grounded in the theoretical
literature around task analysis, cognitive demands, expert
judgments and cognitive processes under the conditions
of the varying degrees of certainty. This limitation was ad-
dressed in the studies reported below.
Aims and overall approach
We report on PD_Manager, a case study of clinicians’ user
needs for the development of a mHealth-based CDSS de-
signed to help clinicians to monitor motor and non-motor
symptoms using easily portable devices such as smart
phones, wristbands and sensor insoles, worn by patients,
to capture objective data about their fluctuating condition.
The system is intended to combine machine learning and
decision support methods with mobile and cloud-based
approaches and share data via the cloud enabling clini-
cians to follow patients’ status closely. In this way, the
PD_Manager CDSS enables continuous and accurate pa-
tient monitoring and PD symptoms assessment, delivered
in a timely manner (see Fig. 1).
The aim of the mHealth-based CDSS is to enable the
monitoring of patients, fluctuation of a range of symp-
toms or medication/treatment adherence, so that man-
agement plans can be evaluated and indications for
modifications to medication regimens identified. The
models for PD_Manager CDSS were developed through
a combination of data mining of various PD symptoms;
expert modelling using a qualitative multi-criteria
method DEX, and assessment of models in terms of clas-
sification accuracy, transparency, correctness and com-
pleteness. This methodology is reported in a separate
publication [40].
Due to the nature of the decision making (i.e. medica-
tion changes in a progressive chronic disease), which
rarely if ever regards life threatening or emergency
events, Quality of Services (QoS) aspects such as latency,
priority and bandwidth were not critical for the develop-
ment of the CDSS. Data loss was minimized as much as
possible given that the system adopted commercial sen-
sors. Other QoS aspects, such as power consumption
were very important for the patient experience with the
system and were taken into consideration both for the
Fig. 1 Implementation of the CDSS for the clinician
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design of the system and for the pilot implementation.
Data security was also addressed in the design and im-
plementation of the mHealth system and was the main
requirement for QoS within the PD_manager context.
In order to develop an initial set of principles for
the CDSS, a series of user-needs studies were initially
conducted, which we are reporting in this paper. The
overall objective of our user-centred approach was to
identify:
I. What types of decisions clinicians make when
managing a patient with PD?
II. Information needs of the clinicians: What factors
and their combination related to the patient
symptoms inform their decisions?
III. Judgement under conditions of varying degree of
certainty: What is the perceived value of self-
reported patient data vs mHealth-generated data for
a range of clinical decisions?
The following suite of three studies were conducted:
Study 1 - Hierarchical Task Analysis (HTA) including
elicitation of user needs, cognitive demands and
perceived risks/benefits (ethical considerations)
associated with the proposed CDSS.
Study 2 - Computational modelling of clinicians’
decision strategies.
Study 3 - Vignette-based study of the relative value of
self-reported vs CDSS-generated evidence for clinicians’
decision making.
Study 1 utilised HTA through structured qualitative in-
terviews, [41] as the framework for examining tasks associ-
ated with the clinical management of PD in terms of goals
and sub-goals as well as the ethical considerations likely to
arise when clinicians use mHealth-based CDSS. HTA, a
core ergonomics methodology, is the established precursor
for exploration of cognitive demands associated with hu-
man performance across a wide variety of domains and
applications.
Study 2 is grounded in social judgement theory and re-
lated methodology [42]. This method has been used in
many areas, and there has been extensive research on
clinical judgement using it in a number of medical do-
mains including studies of chronic heart failure [43], the
management of rheumatoid arthritis [44], and decisions
to use dialysis [45]. This approach aims to describe judg-
ments through the combination of cues, such as signs or
symptoms that are used to diagnose a cause or predict
an outcome. Previous research on Parkinson’s disease
has identified a comprehensive set of symptoms of rele-
vance to managing the disease [24, 46]. Whilst this ob-
jective set of symptoms provides a useful framework of
possibilities, which of these symptoms users actually use
in their judgement process is a different question. A
common finding across all domains of professional judg-
ments, including medical judgments, is that the cues
people actually use in their decisions are not the same as
the cues they explicitly report using [47]. Experts use
less information when making decisions than novices
[48] and often disagree about their judgments [48]. Fully
understanding user needs therefore requires an approach
that captures the variation, context, and subjective
weighting of each piece of information for individual
users.
Study 3 builds on this recognition of the need to context-
ualise experts’ medical decision making by further explor-
ing the situated nature of these judgements. It recognises
the importance of understanding whether and to what ex-
tent clinicians perceive a certain piece of evidence as in-
formative as a function of whether it comes from a
subjective (e.g., patients’ self-reports, diaries) or from an ob-
jective (e.g., wearable technology, electrophysiological and
neuroimaging techniques) source [35, 36]. In addition, we
explore the uncertainty inherent in evaluating these types
of evidence in situ by varying the degree to which the evi-
dence from the two sources are congruent with each other.
We deploy vignettes, a methodology that has already been
successfully used to study how novices and experts make
judgements in conditions of uncertainty based on patients’
self-reports as well as objective evidence, such as a physical
symptom [49–51].
The data were collected between 2015 and 2017. Since the
three studies collected data from clinicians (not patients), a
formal ethical approval was not required within any of the
national legislations (UK, Greece, Slovenia and Italy). How-
ever, within the UK, Research & Development approval from
the hospital trusts - the two hospitals that allowed access to
the clinicians - was obtained. For each study, written In-
formed Consent was obtained from the participants.
Method
Study 1: Hierarchical Task Analysis
Data were collected across four culturally diverse sites (UK,
Italy, Slovenia and Greece) and from two core user groups:
Prescribing clinicians (consultant neurologists, hospital doc-
tors, general practitioners (GPs) and Parkinson’s disease
nurse specialists (PDNS) and supporting clinicians (physio-
therapists, occupational therapists, psychologists, speech
therapists). A mixed-method approach was used whereby
Prescribing Clinicians were interviewed one-to-one and
Supporting Clinicians were either interviewed one-to-one or
took part in a small focus group. The Prescribing and Sup-
porting Clinicians recruited for the study are detailed by
country (Table 1).
The added value of our cross-cultural approach is the
ability to account for diverse models of clinical work
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organisation. Whilst working in multi-disciplinary teams
for complex neurological diseases such as PD is standard
practice in state medical systems such as UK, Italy and
Slovenia, the Greek system is characterised by a predom-
inant role of consultant neurologists within the state sys-
tem, supplemented by specialist treatment in the private
system.
The first step was to clearly define the overall task
under analysis and the specific purpose for that analysis.
Within this study the top-level task and goal were col-
lectively defined as:
‘Effective management of Parkinson’s disease in
order to identify where the proposed outputs of the
PD_manager project can add value to the task’.
There followed a desk-based review of current practice
from the literature resulting in the development of a
preliminary Hierarchical Task Diagram (HTD). Utilising
this preliminary HTD as a stimulus, data were collected
from the prescribing and supporting clinicians via struc-
tured qualitative interviews (locally, within each of the 4
countries) to expand our understanding of the task, to
determine task sub-goals and ultimately to achieve full
task decomposition. During the interviews clinicians
were asked to reflect on the preliminary HTD and sug-
gest any changes/amendments to accurately reflect the
broadest range of tasks they typically undertake. Cogni-
tive demands, decision-making strategies, perceived use-
fulness of symptomatic data, perceived importance of
patient adherence, supporting therapies and beliefs
about mHealth-based CDSS (including ethical consider-
ations) were elicited in parallel by a generalist approach
within the interview to allow us to encompass the whole
domain more effectively.
Study 2: Modelling clinicians’ decision strategies
The aim of this study was to develop a model of how clini-
cians use information from patients with Parkinson’s
disease in the management of PD using a factorial survey
design. We elicited the decision-making strategies of clini-
cians, describing how strongly weighted each of the factors
are within their overall judgements. Prescribing clinicians
assessed 24 cases, each one describing the symptoms of a
different patient. For each case, clinicians were asked to
make judgements about the patient. Specifically, they
made judgements about changing the care plan, change to
Levodopa, and change to dopamine agonist. In each case,
13 key symptoms or factors in the assessment of Parkin-
son’s disease were varied systematically. These were: bra-
dykinesia, rigidity (stiffness), tremor, gait and balance,
sleep, cognitive functioning, depression, constipation,
motor fluctuations, dyskinesia, impulsivity, age and em-
ployment status. The changes in these symptoms were de-
scribed to clinicians in terms of a comparison to a
consultation three to 4 months previously. That is, each of
the symptoms was described as ‘better’, ‘same’, or ‘worse’
than three to 4 months previously. Two contextual factors
were: age (either ‘55 years old’ or ‘75 years old’) and em-
ployment status (either ‘employed’ or ‘retired’). Partici-
pants were informed that in all cases they should assume
that the patient with Parkinson’s disease was currently
taking Levodopa and a dopamine agonist, the disease dur-
ation is 5–10 years and their disease severity is stage 3 on
the Hoehn and Yahr scale [52] (please see the Table 2 for
an example of a case).
Study 3: vignette study of value of different types of
information for clinicians’ diagnostic strategies
The study aim was to investigate clinicians’ decision mak-
ing about treatment and care plans based on the relative
utility of subjective (reported by a patient with Parkinson’s
disease) or objective (digital health) information. Prescrib-
ing clinicians completed an online questionnaire with 15
vignettes describing situations involving hypothetical pa-
tients with Parkinson’s disease (the surnames used in the
vignettes were not of real patients). For all vignettes, the
main information about the patients was kept constant:
Table 1 Participant description
UK
n = 6
Italy
n = 15
Greece
n = 8
Slovenia
n = 18
Total
N = 47
Prescribing clinicians
Consultant neurologist 2 4 8 7 21
Parkinson’s disease nurse specialist 3 – – – 3
General practitioner 1 5 – 3 9
Supporting clinicians
Physiotherapist – 2 – 2 4
Occupational therapist – 1 – 2 3
Psychologist – 3 – 2 5
Speech therapist – – – 2 2
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they were described as older (between 66 and 70 years
old), living with their partner, with their symptom severity
at Hoehn and Yahr stage 3, disease onset was 7 years ago,
and the current therapy as prescribed for the past 6
months. Furthermore, we randomly varied the patients’
gender across the 15 vignettes.
Two within-participant variables were manipulated in
these vignettes: information type (5 levels) and symp-
toms/signs (3 levels). We manipulated the type of infor-
mation presented to the clinicians as follows (see
Table 3): subjective information (patients’ self-report);
objective information (digital health data); congruent
subjective and objective information (both sources sug-
gested a decline in patients’ symptoms/signs); incongru-
ent subjective and objective information (one indicating
a decline and the other indicating an improvement).
For each information type, we devised three different
scenarios where the main difference was the symptom/
sign: (1) bradykinesia [53, 54], and impaired dexterity, (2)
gait and postural stability, and (3) sleep. The following is a
sample vignette presented to participants depicting a case
of incongruence between the patient’s self-report (indicat-
ing a decline in gait and postural stability) and a sensor in-
sole (indicating an improvement):
“Mr Briggs is 69 years old, retired, and he lives with his
wife. He suffered from the first symptoms of PD ap-
proximately seven years ago (Hoehn and Yahr stage 3).
In a consultation with you, the patient tells you that
he feels that his condition has worsened and he has
been experiencing more falls and gait difficulties.
Data from the patient’s sensor insole, a device which
has captured information on his PD symptoms, show
that he has improved and has experienced a
decreased number of falls and gait difficulties since
his last clinical consultation.
The patient has been receiving medication and
physiotherapy treatment over the last 6 months.”
After reviewing each vignette, participants were asked to
select a decision about the therapy (“Based on this infor-
mation, how likely would you change the patient’s care
plan?”) using a 7-point Likert scale (1 = very unlikely, 7 =
very likely), and about the confidence in the decision
(“How confident are you in the answer you have just
given?”, 1 = not at all confident, 7 = very confident). Fi-
nally, they were asked to indicate what type of data they
would find more useful in order to increase confidence in
their decision – subjective (PD patient’s self-report) or ob-
jective (devices-generated) data (“Given your decision,
how useful would you find it to seek for more information
from the patient or the devices to increase your confi-
dence?”). They used two 7-point Likert scales (1 = not at
all useful, 7 = very useful) to provide their answer for both
the self-report and the device-generated data.
After completing the vignettes, participants’ socio-
demographic data (including age, gender, and nationality)
were collected. The survey lasted approximately 30min.
Results
Study 1: Hierarchical Task Analysis
Analysis of the qualitative data comprised a mixture of
summative content and thematic analysis [55]. Coding
structures were developed to guide the analysis of the
data and ensure a harmonized and standardized ap-
proach to analysis of the data across the different coun-
tries. The resultant data were used to develop an
updated version of the Hierarchical Task Diagram vali-
dated by the interview process (Fig. 2).
Table 2 An example of the Study 2 case
Demographics Motor Symptoms Non-motor symptoms Treatment adverse effects
75 years old, retired Bradykinesia Worse Sleep Better Motor fluctuations Same
Rigidity (stiffness) Worse Cognitive functioning Same Dyskinesia Better
Tremor Worse Depression Same Impulsivity Better
Gait & balance Same Constipation Better
Table 3 Information about the manipulated information type variable in Study 3
Variable Levels
Information type Subjective
(self-report)
Objective
(device outcome)
Subjective & objective –
congruent
Subjective & objective –
incongruent
Self-report: decline
Devices: improvement
Subjective & objective
–incongruent
Self-report: improvement
Devices: decline
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The majority of clinicians interviewed in this study op-
erated in an environment with little or no access to con-
tinuous objective data on PD motor symptoms to
support their clinical decision making, even at its most
basic level. Therefore, the provision of this type of data
in graphical form by the mHealth-based CDSS was
deemed to be useful. Having identified the cognitive de-
mands and difficulties clinicians experienced when man-
aging patients and their expressed needs (Appendix 1) as
well as the perceived usefulness of data on the various
motor and non-motor symptoms (Appendix 2), a set of
user-derived requirements for the mHealth-based CDSS
design were proposed (Appendices 3 and 4).
Approaching the development of user needs using this
methodology, the outcomes of this study suggested a move
away from the traditional silos of ‘motor’ and ‘non-motor’
symptom evaluations and suggest that presenting data on
symptoms according to goal-based domains would be the
most beneficial approach. This innovative goal-based do-
main approach including: Diagnosis indicators; Disease pro-
gression indicators; Pharmacological decision support;
Patient safety; Overall QoL indicators; Physiotherapy/Occu-
pational therapy; Psychology and Speech therapy (Appendix
3) would facilitate the collation/integration of the relevant
non-motor symptom data with the motor symptom data for
each of these domains in more targeted and user-friendly in-
terfaces. Furthermore, the data suggested that the most use-
ful symptoms to evaluate should be driven by the
importance the patient themselves attribute in terms of their
overall QoL. Therefore, it was suggested that design should
deliver functionality to allow for the creation of personalised
user interfaces that provide flexibility for clinicians/patients
to identify and select which symptoms they wished to con-
sider at any one time. The availability of such a flexible sys-
tem should allow clinicians to focus on the data they needed
to engage with, to better facilitate patient engagement in
shared decision making and potentially achieve better adher-
ence and clinical outcomes.
Finally, the content analysis of attitudes towards the tech-
nology and ethical issues indicated that the participants were
not aware of any ethical issues associated with the mHealth-
based CDSS. There seemed to be a general agreement that
the systems needed to manage privacy concerns were
already in place such as, for instance, data management pro-
cesses and consent forms. However, when asked whether
they were aware of any governance guidelines /codes of
practice regarding the collection and transmission of patient
data using technology, none of the participants were able to
refer to these systems within the context of their work.
Study 2: Modelling clinicians’ decision strategies
Twelve prescribing clinicians (7 males and 5 females), with a
mean age of 45.58 years, (SD = 8.76) from 4 countries: Italy
(n= 3), Greece (n = 2), Slovenia (n = 3) and the UK (n = 4)
took part in the study. They were consultant neurologists
(n= 9), consultant gerontologist (n= 1) and general practi-
tioners (n = 2). These clinicians saw a mean of 172.67 pa-
tients with Parkinson’s disease per year (SD= 215.26).
Multiple regression was used for each clinician to determine
the weighting of each of the factors on each of the judge-
ments. The judgement patterns were calculated for each
participant individually based on their responses to the
Fig. 2 Hierarchical Task Analysis Diagram reflecting sub-goals and task operations for both Prescribing and Supporting Clinicians
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judgement task. Each of the factors within the cases was
coded as an independent variable and the judgements made
about each case were the dependent variables. The R2 value
for the regression model describes how well the factors ex-
plain the judgements made and the standardised beta
weights for each factor describe the weighting of that factor
in the judgement. Table 4 presents the beta weights for each
factor in each judgement and the R2 for each model.
Across the different models, findings showed that clini-
cians were more likely to change the care plan and in-
crease the level of medication when presented with
worsening symptoms, with the exception of a reduction in
Levodopa with worsening dyskinesia and a reduction in
dopamine agonist with worsening impulsivity. Analysing
the findings in more detail provides some more specific
results. Across the different judgements, the factors that
dominate the decision are motor symptoms: bradykinesia;
rigidity; motor fluctuations; and tremor. Non-motor
symptoms such as depression, impulsivity and cognitive
function explained some variance in the judgements, al-
beit less than bradykinesia, rigidity, motor fluctuations
and tremor, but sleep and constipation had very little ef-
fect on the judgements made. Some factors were weighted
more similarly by all clinicians, e.g. tremor, whereas others
were weighted more differently, e.g. bradykinesia. Further-
more, the study shows that different factor combinations
(e.g. symptom, age, employment status) are important
when making judgments about different questions (e.g.
changing the care plan, change to Levodopa, and change
to dopamine agonist).
Study 3: Vignette study of value of different types of
information for clinicians’ diagnostic strategies
Participants were N = 18 (10 females; 8 males) prescribing
clinicians practicing in Greece (8), Italy (5), the UK (4),
and Slovenia (1). Their mean age was 41.94 (SDage = 7).
They were consultant neurologists (13), general practi-
tioners (2), consultant gerontologist (1), neurology resi-
dent (1), and researcher (1).
In our analyses, given that our main variable of interest
was Information Type, we averaged participants’ responses
across the three primary symptoms. The results indicated
that the clinicians were equally likely to change the care
plan based on information from the patients’ self-report
and the devices about the decline of their condition. In
addition, they were more likely to revise the care plan
when they received congruent information from both
sources and less likely to revise the care plan when they re-
ceived conflicting information from both sources (Fig. 3).
The findings about clinicians’ confidence in their deci-
sion mirrored these findings. Clinicians were equally
confident in changing the care plan when receiving in-
formation from only one information source, most
confident when the information from both sources was
congruent and least confident when it was incongruent.
Discussion
As highlighted by Castro et al. [56] a crucial question to ask
in the development of a CDSS is: What is the system
intended for? Therefore, the early understanding of user
needs is the most important aspect of system development.
And yet, the predominance of the software engineering-
driven CDSS development with a main focus upon informa-
tion needs of a user and use cases based on the already estab-
lished prototypes [24], is unlikely to provide a full account
of the social (e.g., the interactions between patients, care-
givers, and clinicians; time constraints) and psychological
(e.g., clinicians’ judgement and decision-making strategies)
realities within which the technology will be operationalised.
We addressed these shortcomings in our research.
Our approach to user studies was developed to identify
the core principles of design to guide an early develop-
ment of the CDSS. Based on our findings, we can formu-
late three main principles of design with some important
theoretical and practical implications: 1) enabling shared
decision making between the clinician, patient and the
carer; 2) flexibility that accounts for diagnostic and treat-
ment variation among clinicians; 3) monitoring of infor-
mation integration from multiple sources.
Implications for the system design
Our study highlighted that the primary goal of the system
should be to enable shared decision making between the
clinician (e.g., neurologist, PD nurse, physiotherapist), pa-
tient and the carer [57, 58]. This is evident in several
Table 4 Standardised beta weights for the mean response to
identify the factors predicting changes to treatment
Factor Care Plan Levodopa Dopamine Agonist
Bradykinesia .36 .31 .14
Tremor .51 .47 .44
Gait −.02 .16 −.04
Dyskinesia .19 −.29 .31
Motor Fluctuations .44 .44 −.16
Sleep .10 .04 .19
Cognition .23 .27 .00
Impulsivity −.09 −.07 −.36
Depression .22 .08 .27
Constipation −.02 −.10 .06
Rigidity .35 .41 .34
Age −.31 −.07 .00
Employment −.37 −.29 .26
Model R2 0.82 0.90 0.70
N.B. for symptoms, a positive beta weight implies an increased likelihood of
change to the care plan, or an increased level of medication, in response to
worsening symptoms
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findings: our HTA interview study (Study 1) has highlighted
that the needs of clinicians should be conceptualised in
terms of how the system is likely to support the clinician-
patient interaction. The practical implication of this finding
is that the design should be driven by the patient-specific
goal-based domains rather than the expert-defined symptom
categorisation. Study 1 identified that the most useful symp-
toms to evaluate should be decided by the importance pa-
tients themselves attribute to those symptoms in terms of
their overall QoL. A mHealth-based CDSS should therefore
be conceptualised as a vehicle that facilitates co-production
of disease management solutions and should be embedded
within the context of patient-clinician interaction.
The shared nature of decision making extends the ap-
proach to decision making applied in Study 2. Previous
work applying social judgement theory to clinicians’ deci-
sion making uses a paradigm in which an individual clin-
ician is presented objective information and forms a
judgement about the patient. From this analysis their per-
sonal evaluation can be inferred [43–45]. The context of
this study demonstrates that an individual clinician’s
weighting of cues is not the only consideration. Instead,
the weighting of symptoms and desirability of outcomes
may emerge through the interactions of clinicians, patient,
and carer. Study 3 extends the approach to decision mak-
ing, demonstrating how the weighting of this information
is also influenced by its source – the patient’s subjective
report or digital device, thus highlighting again the key
role of the clinician-patient interaction and communica-
tion. The unique context of mHealth devices, in compari-
son to digital devices in more established settings such as
hospitals, further influences their interpretation.
Secondly, our suite of studies highlighted that the sys-
tem should take into account diagnostic variation [5] as
well as treatment variation among clinicians. In other
words, a CDSS should allow different judgement patterns
for the disease management to operate for similarly pre-
sented symptoms. The evidence for this principle emerged
from Study 2, which identified similarities in the way clini-
cians evaluate symptoms, which, nevertheless, may be
linked to significant variations in the way in which the dis-
ease is ultimately managed. Whilst the study did not re-
port on the actual causal models underpinning this
variability, it indicated that different users are likely to pre-
fer different information in management of the disease.
This variation is potentially driven by not only symptoms
presentation but also the immediate as well as broader
context of patients’ lives. Again, this illustrates that it is
not possible to define a set of the most important factors
for all cases, but rather, that the system must have an in-
built flexibility to allow the operation of different solutions
representing co-production by clinician and patient, which
would improve the completeness and usefulness of the
model. This flexibility should be combined with a method
Fig. 3 Mean likelihood of changing the patients with Parkinson’s Disease care plan as a function of the different pieces of information presented
to participants in the scenarios (i.e., self-report only, devices’ outcome only, consistent (congruent) or conflicting (incongruent) information from
both sources). Error bars represent 95% confidence intervals
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to optimize the quality and overall performance of the
decision-making process. The recent developments in
quality of service-based web- service selection [59] may be
one way forward in the identification of the most import-
ant factors that address user needs and increase user satis-
faction whilst maintaining system flexibility.
Finally, our work pointed to the necessity for a system to
fully account for and continuously monitor the shortcom-
ings, risks and compromises inherent in integrating quanti-
tatively different types of information from multiple sources.
Study 3 provides evidence that the combination of informa-
tion from the patient and from the mHealth devices can dif-
ferentially influence experts’ decisions and their confidence
in those decisions. This is demonstrated by the statistically
significant differences between the conditions in which both
types of information were presented (i.e., the congruent and
incongruent conditions) and the conditions in which only
one source of information (either the patients’ self-report or
the devices’ outcomes) was available. The lack of difference,
both in terms of their impact on the care plan revision and
the confidence levels, between the patients’ self-reports and
devices’ outcomes suggests that clinicians consider the - os-
tensibly subjective - information provided by patients as
equally useful and trustworthy as the objective information
generated by the devices. This finding about the clinicians’
reliance on subjective as well as objective evidence is incon-
sistent with the view that technology-based evidence is un-
biased, more ecologically valid, and more reliable than
subjective assessment [32, 33, 60, 61]. It supports our first
principle, however, that puts an emphasis on the patient-
clinician relationship as a focal point of the CDSS.
This finding bears on the actual implementation of a
mHealth-based CDSS. In particular, it would be important
to identify conditions, risks and mechanisms that could give
rise to conflicting information and the impact that this could
have on disease management and patients’ care. Mechanisms
and procedures could then be put in place to deal with these
situations as well as to prevent circumstances in which clini-
cians are reluctant to change the treatment (as it was the
case in the presence of conflicting information from the pa-
tients and the devices in Study 3). These are situations that
can generate technical uncertainty, whereby paradoxically
the knowledge is inadequate, even if data and technology are
available [4]. Furthermore, uncertainty could be used to jus-
tify risk discounting or inaction [62, 63], mHealth based
CDSS should therefore not only provide appropriate and re-
liable evidence to aid clinical judgments, but also aim to re-
duce the uncertainty inherent in natural decision-making
contexts experienced by clinicians –when a clinician and a
patient are actually interacting.
Finally, we would like to comment on one surprising find-
ing indicating that, at the time of the interviews, the clini-
cians appeared to have no ethical concerns associated with
the advent of machine learning and mHealth into their
clinical practice. Ethical judgments of clinicians are currently
covered by the established principles of medical decision
making - the Hippocratic Oath of “do no harm” and the
Helsinki declaration [64] of having appropriate oversight of
data management and the need to seek patient consent.
However, the huge advances in the field of Artificial
Intelligence and mHealth must be accompanied by rapid
education to prepare clinicians for assessing the ethical im-
plications of using these systems in their interactions with
patients. Of particular concern is the issue of the account-
ability of technology – both in terms of its ability to provide
trusted and relevant information, but also in terms of its abil-
ity to recount and feedback the way in which algorithms are
providing the data for the mHealth-based CDSS (explainabil-
ity). This directly links to the issue of how the assessments of
accountability and responsibility of the clinician can be estab-
lished in situations where they may not be able to assess the
reliability or usefulness of information that technology pro-
vides, and when they may not be able to meaningfully assess
the consequences of their judgments. It is the latter issue that
calls for clinicians’ critical awareness of the nature of such
technology and the possible biases that may be perpetuated
throughout the life cycle of a technological system. Engaging
clinicians in these discussions is essential in order to prevent
the deterioration of patient trust and ensure effective health-
care delivery based on any future mHealth CDSS.
Future research should seek to explore the relevance of
the core principles for mHealth-based CDSS development
identified by this study in the Parkinson’s domain in other
chronic disease domains. We focused on a specific, multifa-
ceted, and fluctuating neurodegenerative disease, but it is
possible that for each chronic-disease domain these core
principles may need to be tailored to some degree. However,
the utilisation of the theoretical and methodological frame-
work described here would facilitate the identification of any
domain-specific issues.
Conclusions
Being guided by psychological theory enabled us to move
beyond mere information -gathering to develop core princi-
ples for designing a Parkinson’s mHealth based CDSS. We
developed a novel approach to address the questions of the
system’s core purposes, which provided a more nuanced ac-
counting of clinician judgment in situ and helped formulate
a vision for the mHealth-based CDSS system functionalities.
This vision highlights the central importance of the patient-
clinician relationship in clinical decision-making and the
relevance of theoretical as opposed to algorithm (technol-
ogy)-based modelling of human judgment. It challenges the
assumption that augmented decision making - based on the
operation of algorithms - is the best solution to better clin-
ical decision making, instead establishing human decision
making as central in the increasingly machine- and data-
driven world of healthcare.
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Appendix 3
Table 7 Prescribing Clinicians’ User Interfaces – Proposed data requirements per goal related domains
Suggested data provision for each User Interface Domain
UI_1A
Diagnosis Indicators
UI_1B
Disease Progression Indicators
UI_1C
Pharmacological Decision Support
UI_1D
PwP
Safety
UI_1E
Overall QoL
Motor Symptoms Data
Tremor √ √
Muscle Rigidity √ √ √
Bradykinesia √ √ √
Gait/Postural Balance √ √ √ √
Dyskinesia √ √
On Off fluctuations/ Freezing √ √ √ √
Speech Disorder √ √
Dysphagia √ √ √
Non-motor Symptoms Data
Cognitive Disorders/Dementia √ √ √ √
Depression and Anxiety √ √ √
Impulse control disorders √ √
Sleep disorders/Daytime sleepiness √ √
Dizziness/Fainting √ √
Fatigue √
Sweating √
Urinary/ Constipation Problems √
Nausea/ Gastro-intestinal problems √
Other Supporting Data
Video of PwP symptoms √ √ √ √
Speech quality recordings √ √
Overall activity levels √ √ √ √
Number of falls/time √ √ √ √
Pain index √ √
Hallucination incidence √ √ √
Blood Pressure/time √ √ √
Bodyweight/time √
Daily fluid intake √
Adherence to care plans
Pharmacological √ √
Nutritional √ √
Physiotherapy √ √
Speech √ √
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Appendix 4
Table 9 User derived requirements for PD_manager design
Requirement Details
R1 Motor and non-motor symptom outputs should be in a quick and easy to understand graphical format.
R2 Clinician needs to be able to easily identify/compare changes in symptoms overtime and drill down into different time periods
depending on the needs of the patient.
R3 Provide video capture data to help establish the difference between Dyskinesia and Tremor in patients’ self-report.
R4 Data provision should facilitate the ability to establish the co-occurrence of, and comparison of, motor with non-motor symptoms
R5 The User Interface should provide flexibility for the clinician to choose, in conjunction with the patient which symptoms and data collection
options/time periods are of most interest for a particular patient and be able to explore these in the context of a personalised integrated
data output.
R6 Provide the clinician and patient/caregiver with data on patient’s adherence to pharmacological and supporting therapy care plans over time.
R7 Provide the clinician and patient/caregiver access to an up-to-date list of a patient’s current prescribed pharmacological care plan
(e.g. drug name, format, dosage etc.).
R8 Provide the clinician and patient/caregiver with access to an up-to-date list of patient’s current prescribed supporting therapy care
plans so that they have a view of all the activities that should be taking place i.e. for a GP it would be useful to be able to see whether
a PD nurse specialist had prescribed changes to a care plan. Similarly it would be useful for a physiotherapist to be able to see what
occupational therapy plans had been prescribed etc. thus facilitating a better understanding of the overall care being provided across
the multidisciplinary team (MDT).
R9 Provide the clinician with the ability to monitor the effectiveness of the step-by-step changes made to pharmacological care plans
both at and between face-to-face consultations (i.e. remotely) to establish if the change has resulted in a positive/negative outcome.
R10 Provide the clinician and patient/caregivers with the ability to access data on patient’s activity levels/duration in their home environment.
R11 Provide the clinician with the ability to prescribe supporting therapies a patient can engage with at home and provide data on
patient’s adherence/performance indicators when they have engaged with these therapies via the PD_manager platform (e.g.
gamification of physio, cognitive activities, speech and nutrition).
R12 Provide a communication platform to facilitate the sharing of information and alerts between clinicians participating in the care of a
patient in the context of an MDT.
R13 Provide functionality to alert patient/caregiver with when they should take their medication.
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